<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1937">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666207</url>
  </required_header>
  <id_info>
    <org_study_id>H-20028631-1</org_study_id>
    <nct_id>NCT04666207</nct_id>
  </id_info>
  <brief_title>Viral Shedding, Symptoms and Exposure of SARS-CoV-2 in Non-hospitalized Children With COVID-19</brief_title>
  <official_title>A Cohort Study of Non-hospitalized SARS-CoV-2 Positive Children in Denmark: Viral Shedding, Symptoms and Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data on COVID-19 in children are still scarce, and their role in SARS-CoV-2 transmission is&#xD;
      poorly described. Furthermore, documentation of the best SARS-CoV-2 sampling methods in&#xD;
      children are limited. In adults, saliva seems like a promising specimen to collect by&#xD;
      noninvasive procedure to diagnose and monitor viral load of SARS-CoV-2, but this has not been&#xD;
      tested in children yet.&#xD;
&#xD;
      We want to test the following hypothesis:&#xD;
&#xD;
        1. Shedding load and duration of SARS-CoV-2 in children are related to age, gender,&#xD;
           clinical symptoms and exposure&#xD;
&#xD;
        2. Salvia samples have equal or higher sensibility than nasal swaps in children for&#xD;
           detection of SARS-CoV-2&#xD;
&#xD;
        3. Parental home testing of saliva and feces is feasible in children&#xD;
&#xD;
      The study is a prospective cohort study of SARS-CoV-2 PCR-positive children from two test&#xD;
      centers in the Capital Region of Denmark. Children aged 0-17 years with a PCR-positive&#xD;
      SARS-CoV-2 test from a nasal or pharyngeal swab is included from May 2020 to January 2021 and&#xD;
      followed-up for a period of 28 days with weekly sample collection and questionnaires.&#xD;
&#xD;
      Samples include a saliva sample, a nasal swap and a rectal swap for children under four years&#xD;
      of age. A semiquantitative RT-PCR method, will identify positive and negative samples and&#xD;
      provide a Ct value estimating viral load. Saliva and fecal samples will be analyzed from&#xD;
      November 2020-February 2021.&#xD;
&#xD;
      Shedding duration will be related to medial history, clinical presentation, exposure, gender&#xD;
      and age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Salvia samples have equal or higher sensibility than nasal swaps in children for detection of SARS-CoV-2</measure>
    <time_frame>1 year</time_frame>
    <description>Measured by RT-PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parental home testing of saliva and feces is feasible in children</measure>
    <time_frame>1 year</time_frame>
    <description>measured by a questionnaire</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PCR</intervention_name>
    <description>RT-PCR for SARS-CoV-2</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      feces, saliva, nasal secretions&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        SARS-CoV-2 PCR-positive children from two test centers in the Capital Region of Denmark&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a PCR-positive SARS-CoV-2 test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrikka Nygaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrikka Nygaard, MD, PhD</last_name>
    <phone>+45 35459761</phone>
    <email>ulrikka.nygaard@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Louise von Linstow, MD, PhD</last_name>
    <phone>+45 35459722</phone>
    <email>marie-louise.von.linstow.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrikka Nygaard, MD</last_name>
      <phone>35453545</phone>
      <phone_ext>+45</phone_ext>
      <email>ulrikka.nygaard@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Allan Bybeck Nielsen</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

